Skip to main content

Celltrion receives FDA nod for Prolia, Xgeva biosimilars

Denosumab is used to improve or protect bone health in patients with osteoporosis.
Levy

Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and Xgeva (denosumab) respectively.

"The approval of Stoboclo and Osenvelt is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture as well as cancer-related skeletal events," said Thomas Nusbickel, chief commercial officer at Celltrion USA. "Patients deserve therapeutic options that have the potential to make real impacts on their care and their lives. We are committed to continuous innovation to meet these goals leveraging our experience and successful track record with biosimilar and novel biologics."

"Denosumab is used to improve or protect bone health in patients with osteoporosis or those undergoing various cancer treatments and as a therapy for a lifetime for postmenopausal osteoporosis (PMO) patients," said Prof. Jean-Yves Reginster, Professor of Medicine, Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia and director WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging, Liège, Belgium. 

[Read more: Pharmaceutical firms launch Stelara biosimilarS]

Reginster added, "Biosimilars have expanded into new therapeutic areas such as immunology, oncology and ophthalmology as they continue to offer significant cost-saving potential while expanding patient access. Having a denosumab product with a clinically proven track record in quality and safety is a valuable addition for my patients."

In accordance with a settlement agreement with Amgen, Stoboclo and Osenvelt are expected to be available in the United States in June 2025.

[Read more: FDA accepts Alvotech, Teva's BLAs for Simponi biosimilars]

X
This ad will auto-close in 10 seconds